Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-10 09:39 am Sale |
2022-12-31 | 13G | AnaptysBio, Inc. ANAB |
Flynn James E | 1,161,826 4.090% |
-304,774 (-20.78%) |
Filing History |
| 2023-02-10 09:37 am Sale |
2022-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
Flynn James E | 2,052,010 5.770% |
-2,784 (-0.14%) |
Filing History |
| 2023-02-10 09:36 am Sale |
2022-12-31 | 13G | Merus N.V. MRUS |
Flynn James E | 2,380,438 5.140% |
-141,115 (-5.60%) |
Filing History |
| 2023-02-10 09:34 am Unchanged |
2022-12-31 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
Flynn James E | 2,032,335 5.510% |
0 (Unchanged) |
Filing History |
| 2023-02-10 09:33 am Purchase |
2022-12-31 | 13G | HilleVax, Inc. HLVX |
Flynn James E | 2,694,101 8.080% |
76,153 (+2.91%) |
Filing History |
| 2023-02-10 09:32 am Purchase |
2022-12-31 | 13G | Evolus, Inc. EOLS |
Flynn James E | 3,319,000 5.900% |
288,701 (+9.53%) |
Filing History |
| 2023-02-10 09:30 am Purchase |
2022-12-31 | 13G | Enhabit, Inc. EHAB |
Flynn James E | 2,996,000 6.040% |
150,000 (+5.27%) |
Filing History |
| 2023-02-10 09:28 am Sale |
2022-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 5,884,448 5.650% |
-176,043 (-2.90%) |
Filing History |
| 2023-02-10 09:27 am Purchase |
2022-12-31 | 13G | Brookdale Senior Living Inc. BKD |
Flynn James E | 12,679,651 6.790% |
463,090 (+3.79%) |
Filing History |
| 2023-02-01 5:11 pm Purchase |
2023-01-31 | 13G | GeneDx Holdings Corp. WGS |
Flynn James E | 1,733,094 7.260% |
1,161,928 (+203.43%) |
Filing History |
| 2023-01-18 7:57 pm Sale |
2023-01-17 | 13D | Oncorus, Inc. ONCR |
Flynn James E | 1,015,154 3.910% |
-566,397 (-35.81%) |
Filing History |
| 2023-01-13 6:47 pm Sale |
2023-01-11 | 13D | Oncorus, Inc. ONCR |
Flynn James E | 1,581,551 6.090% |
-954,635 (-37.64%) |
Filing History |
| 2022-12-30 7:15 pm Sale |
2022-12-22 | 13D | Oncorus, Inc. ONCR |
Flynn James E | 2,536,186 9.760% |
-470,747 (-15.66%) |
Filing History |
| 2022-12-29 5:27 pm Sale |
2022-12-29 | 13G | Delcath Systems, Inc. DCTH |
Flynn James E | 0 0.000% |
-500,000 (Position Closed) |
Filing History |
| 2022-12-29 5:25 pm Sale |
2022-12-29 | 13G | Vincerx Pharma, Inc. VINC |
Flynn James E | 0 0.000% |
-68,966 (Position Closed) |
Filing History |
| 2022-12-29 5:24 pm Sale |
2022-12-29 | 13G | Xilio Therapeutics, Inc. XLO |
Flynn James E | 0 0.000% |
-2,154,061 (Position Closed) |
Filing History |
| 2022-12-23 3:35 pm Purchase |
2022-12-23 | 13G | Terns Pharmaceuticals, Inc. TERN |
Flynn James E | 2,851,287 5.940% |
991,287 (+53.30%) |
Filing History |
| 2022-12-21 7:05 pm Purchase |
2022-12-19 | 13D | Oncorus, Inc. ONCR |
Flynn James E | 3,006,933 11.580% |
157,963 (+5.54%) |
Filing History |
| 2022-12-01 4:51 pm Sale |
2022-11-22 | 13G | Frazier Lifesciences Acquisition Corporation FLAC |
Flynn James E | 0 0.000% |
-2,572,986 (Position Closed) |
Filing History |
| 2022-11-23 3:19 pm Unchanged |
2022-11-21 | 13D | Graybug Vision, Inc. GRAY |
Flynn James E | 377,265 24.490% |
0 (Unchanged) |
Filing History |